Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage oncology biopharmaceutical company that entered the public markets through a de-SPAC merger with Panacea Acquisition Corp. II, sponsored by Panacea Acquisition Management II, LLC, with the transaction completing in 2022 following the SPAC's 2021 IPO. The company is focused on developing novel therapies targeting cancer, operating within the healthcare and biopharmaceutical sector. Nuvation Bio submitted an 8-K filing with the Securities and Exchange Commission on September 5, 2024, under accession number 0001193125-24-214241, continuing its routine disclosure obligations as a post-merger public company. For full filing history, sponsor profiles, and deal analytics on NUVB and the broader SPAC universe, sign up at SpacDesk.